Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of RANEXA in this indication is substantial. |
Clinical Added Value
| no clinical added value |
RANEXA should be used only by patients with stable angina that is inadequately controlled or who are intolerant to betablockers and/or calcium channel blockers.
Given the data available, RANEXA does not provide any improvement in actual benefit (IABV) in the management of these patients. |
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
5HGtC9WuS0PY6Gna
